Skip to Main content Skip to Navigation
New interface
Journal articles

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Abstract : Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and selectivity for solid tumors is still required. Here, we describe a novel tandem T-cell recruiting trispecific antibody for the treatment of colorectal cancer (CRC). This construct, termed trispecific T-cell engager (TriTE), consists of a CD3-specific single-chain Fv (scFv) flanked by anti-epidermal growth factor receptor (EGFR) and antiepithelial cell adhesion molecule (EpCAM) single-domain V HH antibodies. The TriTE was well expressed in mammalian and yeast cells, bound the cognate antigens of the three parental antibodies, and enabled the specific cytolysis of EGFR-and/or EpCAM-expressing cancer cells, without inducing T cell activation and cytoxicity against double-negative (EGFR − EpCAM −) cancer cells. Bivalent bispecific targeting of doublepositive HCT116 cells by TriTE improved in vitro potency up to 100-fold compared to single-positive cells and significantly prolonged survival in vivo. In addition, it was less efficient at killing single-positive target cells than the corresponding bispecific controls, leading to potentially enhanced tumor specificity. Moreover, dual targeting of two tumor-associated antigens may contribute toward preventing the tumor escape by antigen loss caused by selective pressures from conventional single-targeting T-cell engagers, and may help to overcome antigenic heterogeneity.
Document type :
Journal articles
Complete list of metadata
Contributor : Patrick Chames Connect in order to contact the contributor
Submitted on : Thursday, August 4, 2022 - 11:28:10 AM
Last modification on : Tuesday, August 30, 2022 - 2:37:24 PM
Long-term archiving on: : Saturday, November 5, 2022 - 6:23:42 PM


Tapia-Galisteo et al. - 2022 -...
Publisher files allowed on an open archive


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License




Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, et al.. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. OncoImmunology, 2022, 11, ⟨10.1080/2162402x.2022.2034355⟩. ⟨hal-03745498⟩



Record views


Files downloads